SLGL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 16:00):

Stats
Today's Volume	44 639.00
Average Volume	29 514.00
Market Cap	19.49M
EPS	$0 ( 2024-05-10 )
Next earnings date	( $-0.150 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.690
ATR14	$0.00900 (1.29%)

Sol Gel Technologies Ltd Correlation

10 Most Positive Correlations
SIRI	0.864
CARE	0.862
FXNC	0.856
CFB	0.849
SFST	0.839
NFBK	0.839
HAIN	0.838
ACLS	0.836
OTEX	0.831
TTEC	0.829

10 Most Negative Correlations
FRLA	-0.832
INCR	-0.832
VITL	-0.826
VTVT	-0.826
IXAQ	-0.819
TRMR	-0.818
TWLVU	-0.813
KNTK	-0.811
RIVE	-0.809
PWP	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sol Gel Technologies Ltd Financials

Annual	2023
Revenue:	$1.55M
Gross Profit:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2023
Revenue:	$1.55M
Gross Profit:	$1.21M (77.99 %)
EPS:	$-1.010

FY	2022
Revenue:	$3.88M
Gross Profit:	$-8.80M (-226.60 %)
EPS:	$-0.590

FY	2021
Revenue:	$31.27M
Gross Profit:	$0.00 (0.00 %)
EPS:	$0.140

Financial Reports:

No articles found.

Sol Gel Technologies Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sol Gel Technologies Ltd

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Realtime updates for Sol Gel Technologies Ltd [SLGL]

Upcoming Earnings Alert

Sol Gel Technologies Ltd Options Data

Calls

Puts